63468-63-3

Usage

Uses

2,5-Dihydro-1H-pyrrole, HCl

Upstream product

• 7153-66-4 <(Z)-4-chloro-2-butenyl>ammonium chloride 
• 77484-76-5 cis-3,4-dibromopyrrolidine hydrochloride 
• 6147-66-6 diallylamine hydrochloride 
• 95-48-7 ortho-cresol 
• 132945-75-6 (S)-tert-butyl 3-(methylsulfonyloxy)pyrrolidine-1-carboxylate 
• 108-39-4 3-methyl-phenol 
• 109-97-7 pyrrole 
• 6913-92-4 1-benzyl-2,5-dihydro-1H-pyrrole 

Downstream Products

• 151692-76-1 1-(6-Bromo-1,3-benzodioxol-5-ylcarbonyl)azacyclopent-3-ene 
• 109-96-6 3-Pyrroline 
• 100350-96-7 trans-3,4-dibromopyrrolidine hydrochloride 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 31970-04-4 1-carboxybenzyl-3-pyrrolidine 
• 90490-64-5 1-(4-methoxyphenyl)-2-(1H-pyrrol-1-yl)ethan-1-one 
• 21399-13-3 1-(2,5-dihydro-1H-pyrrol-1-yl)ethan-1-one 
• 111185-41-2 1-(2,5-dihydro-1H-pyrrol-1-yl)-2,2,2-trifluoroethanone 

Relevant academic research and scientific papers

Synthesis, characterization, and catalytic activity of a ruthenium carbene complex coordinated with bidentate 2-pyridine-carboxylato ligands

The halide and phosphine free complex [(sIMes)(C5H 4N-2-CO2)2RuCHPh] (7) (sIMes = 1,3-dimesitylimidazolidin-2-ylidene) bearing two bidentate 2-pyridinecarboxylato ligands was synthesized from the carbene complex [(sIMes)(PCy 3)(Cl)2RuCHPh] (4) and the silver 2-pyridine-carboxylate (8). The molecular structure of the octahedral complex 7 reveals that the two carboxylato functions are coordinated in cis geometry to the ruthenium center. Catalyst 7 exhibits activity in ring-closing metathesis (RCM) reactions after addition of a cocatalyst (HCl) in dichloromethane as well as in methanol solution.

SUBSTITUENT-INCLUDING UREA COMPOUND

An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases. The present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. (Each symbol in Formula (1) has the same definition as that described in the specification.)

Preparation method of medical intermediate N-BOC-3-pyrroline

The invention discloses a preparation method of a medical intermediate N-BOC-3-pyrroline. The method comprises the following steps: adding a proper amount of benzylamine, 3-bromopropylene, dichloromethane and an alkaline reagent into a reaction bottle for reaction to obtain an enamine compound; dissolving the enamine compound in dichloromethane, adding a catalyst (Grubbs first generation) for reaction, adding anhydrous sodium sulfate after adding water for layering, and performing suction filtration to obtain mother liquor; adding 1-chloroethyl chloroformate and methanol into the mother liquor, debenzylating to obtain pink solid, adding petroleum ether into the pink solid, pulping, and carrying out suction filtration to obtain 3-pyrroline hydrochloride; and re-dissolving the 3-pyrroline hydrochloride with water, adding an alkaline solution of NaHCO3 and (BOC)2O, stirring and reacting, extracting after the reaction is finished, separating out an organic phase, and drying to obtain a finished product of N-BOC-3-pyrroline. The method is low in raw material cost, simple in process step, high in yield, small in pollution, high in product purity and suitable for industrial production.

Water soluble homogeneous catalysts that are recoverable by phase selectivity and host-guest interactions

A chemical reaction is catalyzed in an organic solvent using a water soluble N-heterocyclic carbene homogeneous catalyst to form a reaction mixture. An aqueous phase in the reaction mixture. A solvent in which the catalyst is insoluble is added to the reaction mixture, causing the catalyst to migrate to the aqueous phase to form a catalyst-laden aqueous phase. The catalyst is extracted from the catalyst-laden aqueous phase.

A simple and practical preparation of an efficient water soluble olefin metathesis catalyst

This study details homogeneous olefin metathesis in water catalysed by a di-ammonium functionalised Ru-alkylidene complex. A facile gram scale synthesis of an air stable catalyst precursor which can be readily converted to its water soluble derivative is described. The di-ammonium functionalised Ru-alkylidene complex facilitates a range of ring-closing metathesis (RCM) and cross-metathesis (CM) reactions in water.

Effect of added salt on ring-closing metathesis catalyzed by a water-soluble hoveyda-grubbs type complex to form N-containing heterocycles in aqueous media

The efficiency of ring-closing metathesis catalyzed by a Hoveyda-Grubbs type catalyst in water can be enhanced by addition of a chloride salt under neutral conditions. UV-vis spectroscopic study showed that a characteristic band of the catalyst around 380 nm remained over 16 h in the presence of KCl, whereas the band distinctly decreased in the absence of KCl. The disappearance of the band is ascribed to a displacement of a chloride ligand by a water molecule or a hydroxide anion. The spectral changes can be related to the metathesis activity. The experimental results indicate that avoidance of the chloride ligand loss is important to maintain the metathesis activity in water.

Studies of a soluble polyethylene glycol immobilized ruthenium catalyst in aqueous media

We have developed an air-stable soluble polyethylene glycol bound ruthenium catalyst which performs efficient ring-closing metathesis in organic solvents as well as in aqueous media.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5

A novel series of diaryl bicyclic azole-amines that are potent selective negative modulators of metabotropic glutamate receptor 5 (mGluR5) were identified through rational design. An initial hit compound 5a of modest potency (IC50 = 1.2 μM) was synthesized. Evaluation of structure-activity relationships (SAR) on the left-hand side of the molecule revealed a preference for a 2-substituted pyridine group linked directly to the central heterocycle. Variation of the central azolo-amine portion of the molecule revealed a preference for the [4,5-c]-oxazoloazepine scaffold, while right-hand side variants showed a preference for ortho- and meta-substituted benzene rings linked directly to the tertiary amine of the saturated heterocycle. These iterations led to the synthesis of 29b, a potent (IC50 = 16 nM) and selective negative modulator that showed good brain penetrance, high receptor occupancy, and a duration of action greater than 1 h in rat when administered intraperitoneally. Formal PK studies in rat and Rhesus monkey revealed a short half-life that was attributable to high first-pass clearance.

Convenient preparation of optically pure 3-aryloxy-pyrrolidines

Chiral 3-methanesulfonyl-1-Boc-pyrrolidine and piperidine were reacted with sodium phenolates, resulting in a mixture of displacement and elimination products. Following carbamate deprotection and pH adjustment, the 3-pyrroline and tetrahydropyridine by-products resulting from elimination were easily removed through aqueous partitioning and/or concentration. Although the pyrrolidines were formed with a high degree of optical purity, slight racemization was observed for the piperidine case because elevated temperatures were required to effect displacement. Copyright Taylor & Francis Group, LLC.